A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs
Pharmacology
[키워드] acute respiratory syndrome
alleviate
anti-viral agents
antiviral agent
Antiviral effect
Asymptomatic
benefit
blunt
children
China
Chinese
Chloroquine
clinical
clinical evidence
clinical trial
convalescent plasma
coronavirus disease
Coronavirus-2
COVID-19
COVID-19 patient
Critical
critical COVID-19 patient
cytokine release
Cytokine release syndrome
drug
early stage
Efficacy
Favipiravir
highlight
Hydroxychloroquine
in vitro
Inflammation
inhibit
inhibitor
initial
interferon
interleukin-6
interleukin-6 inhibitors
late stage
Mild
MOST
Negative conversion
non-randomized
observational study
pandemic
Patient
patients with COVID-19
Pediatric case
Prophylaxis
repurposing
review
ribavirin
sample-size
SARS-CoV-2
severe COVID-19 patient
severe patients
small sample size
Study design
therapeutic option
therapy
Traditional Chinese medicine
Treatment
treatment initiation
with mild disease
[DOI] 10.3389/fphar.2020.584956 PMC 바로가기 [Article Type] Pharmacology
[DOI] 10.3389/fphar.2020.584956 PMC 바로가기 [Article Type] Pharmacology